Takeda Pharmaceutical Company Ltd
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
- Conditions
- Hereditary Angioedema (HAE)
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 207
- Registration Number
- NCT04861090
- Locations
- 🇦🇹
LKH-Universitätsklinikum Klinikum Graz, Graz, Austria
🇦🇹Kepler Universitätsklinikum Linz, Linz, Austria
🇦🇹Medizinische Universitat Wien (Medical University of Vienna), Wien, Austria
Drug Use Study of Febuxostat After Recent Changes in the Prescribing Information
- Conditions
- Cardiovascular DiseasesGout
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24046
- Registration Number
- NCT04853160
- Locations
- 🇺🇸
Central Contact, Cambridge, Massachusetts, United States
A Study Using Artificial Intelligence to Identify Adults With Complex Perianal Fistulas Associated With Crohn's Disease
- Conditions
- Crohn DiseaseRectal Fistula
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 32
- Registration Number
- NCT04844593
- Locations
- 🇪🇸
Hospital Universitario Fundacion Alcorcon, Madrid, Comunidad De Madrid, Spain
🇪🇸Hospital del Mar, Barcelona, Cataluna, Spain
🇪🇸Hospital Universitario Son Espases, Palma, Islas Baleares, Spain
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
- Conditions
- Non-small Cell Lung Cancer (NSCLC)Colorectal CancerSquamous Cell Cancer of Head and Neck (SCCHN)
- Interventions
- Drug: TAK-186
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 258
- Registration Number
- NCT04844073
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸University of Colorado Anshutz Medical Campus, Aurora, Colorado, United States
An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease
- Conditions
- Primary Immunodeficiency Disease
- Interventions
- Biological: IGSC 20% infusion
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT04842643
- Locations
- 🇯🇵
Kurume University Hospital, Kurume, Fukuoka, Japan
🇯🇵Gifu University Hospital, Gifu, Japan
🇯🇵Tokyo Medical Dental University Hospital, Tokyo, Japan
A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma
- Interventions
- Other: No Intervention
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 191
- Registration Number
- NCT04840680
- Locations
- 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
A Study of Prucalopride in Breastfeeding Women With Constipation
- Conditions
- Chronic Idiopathic Constipation (CIC)
- Interventions
- Other: No Intervention
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT04838522
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma
- Conditions
- Lymphoma
- Interventions
- Other: No Intervention
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1000
- Registration Number
- NCT04837222
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳The first hospital of Jilin University, Changchun, Jilin, China
Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults
- Conditions
- Healthy Volunteers
- Interventions
- Drug: TAK-994 Oral TabletDrug: [14C]TAK-994 Intravenous InfusionDrug: [14C]TAK-994 Oral Suspension
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 6
- Registration Number
- NCT04833049
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Bioavailability and Food Effect Study of Two Formulations of TAK-906
- Conditions
- Healthy Volunteers
- Interventions
- Drug: TAK-906
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Takeda
- Registration Number
- NCT04831502
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States